Drug Trial Radar · NCT02432833
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
Last checked: Nov 20, 2026Latest source record: Apr 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
428
Actual
Start
May 2015
Primary completion
Jan 24, 2017
Study completion Jan 24, 2017
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- May 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.
Conditions
- End Stage Renal Disease
Interventions
ENVARSUS®Drug
Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
PROGRAF®Drug
Prograf® hard capsules, twice daily, oral formulation
ADVAGRAF®Drug
Advagraf® prolonged-release hard capsules, once daily, oral formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tacrolimus total daily dose (TDD) from week 3 to month 6Time frame: from week 3 to month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chiesi farmaceutici Spa
Parma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.